Financial Performance - Total revenue for the three months ended March 31, 2025, was $9.889 million, compared to $0 in the same period in 2024, representing a significant increase [127]. - The net loss for the three months ended March 31, 2025, was $36.638 million, an improvement of $5.290 million compared to a net loss of $41.928 million in 2024 [127]. - Revenue for the three months ended March 31, 2025, was $9.9 million, primarily from collaboration with Chiesi, including a one-time development cost reimbursement [128]. Research and Development - Research and development expenses for the three months ended March 31, 2025, were $38.041 million, an increase of $5.649 million from $32.392 million in 2024 [127]. - Research and development expenses increased to $38.0 million for the three months ended March 31, 2025, up from $32.4 million in the same period of 2024, reflecting a $5.6 million increase mainly due to costs for seralutinib [129]. - The company has an accumulated deficit of $1.305 billion as of March 31, 2025, reflecting the ongoing investment in research and development [111]. Expenses - General and administrative expenses decreased to $8.658 million in the first quarter of 2025 from $9.567 million in 2024, a reduction of $909,000 [127]. - General and administrative expenses decreased to $8.7 million for the three months ended March 31, 2025, down from $9.6 million in 2024, primarily due to a $1.6 million decrease in stock-based compensation [131]. Cash and Liquidity - As of March 31, 2025, the company had $257.9 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation for ongoing operations [110]. - Cash, cash equivalents, and marketable securities totaled $257.9 million as of March 31, 2025, providing liquidity for ongoing operations [136]. - Net cash used in operating activities for the three months ended March 31, 2025, was $39.7 million, compared to $52.3 million in the same period of 2024 [143]. - Investing activities provided approximately $22.1 million of cash during the three months ended March 31, 2025, primarily from maturities of marketable securities [146]. - Financing activities generated $0.5 million of cash for the three months ended March 31, 2025, mainly from the issuance of common stock [148]. Future Outlook - The company expects to incur significant operating losses for the foreseeable future as it continues the development of seralutinib and seeks regulatory approvals [111]. - Future capital requirements will depend on various factors, including the costs of clinical trials for seralutinib and the ability to generate product revenues [152]. - The company expects to finance its cash needs through equity offerings, debt financings, or other capital sources until it can generate substantial product revenues [113]. - The company expects to finance cash needs through equity offerings, debt financings, or collaborations, but may face challenges in raising additional funds [153]. Clinical Development - The company anticipates activating the first clinical sites for the global registrational Phase 3 SERANATA Study for PH-ILD in the fourth quarter of 2025 [108]. - Under the Chiesi Collaboration Agreement, the total potential transaction value includes a one-time $160 million development cost reimbursement payment [112].

Company Performance - Gossamer Bio reported a quarterly loss of $0.15 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.21 per share a year ago, representing an earnings surprise of 11.76% [1] - The company posted revenues of $9.38 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 19.63%, compared to zero revenues a year ago [2] - Gossamer Bio has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Gossamer Bio shares have increased by approximately 48.1% since the beginning of the year, contrasting with a decline of 4.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on $5 million in revenues, and for the current fiscal year, it is -$0.70 on $23.66 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Gossamer Bio belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Gossamer Bio's stock performance [5]

Financial Performance - Cash, cash equivalents, and marketable securities totaled $294.5 million as of December 31, 2024[11] - Net loss for Q4 2024 was $33.0 million, or $0.15 per share, compared to a net loss of $48.1 million, or $0.21 per share, for the same period in 2023[10] - Total revenue for the full year ended December 31, 2024, was $114.7 million, with $90.7 million from license sales and $24.0 million from contracts with collaborators[10] - The accumulated deficit as of December 31, 2024, was $1.27 billion, compared to $1.21 billion at the end of 2023[11] Research and Development - Research and Development (R&D) expenses for Q4 2024 were $36.1 million, up from $30.0 million in Q4 2023, while full-year R&D expenses were $138.5 million compared to $135.3 million in 2023[10] - A registrational Phase 3 clinical trial in PH-ILD is expected to commence in the second half of 2025[1] - The PROSERA Phase 3 study in PAH is on track for topline data readout in Q4 2025, with enrollment ongoing[1] - Seralutinib received Orphan Drug Designation for PAH in Japan, which may support a marketing application pending clinical trial results[8] General and Administrative Expenses - General and Administrative (G&A) expenses for Q4 2024 were $9.4 million, slightly up from $9.1 million in Q4 2023, with full-year G&A expenses at $36.1 million compared to $38.5 million in 2023[10] Cash Flow and Funding - The company expects its current cash and marketable securities to fund operations into the first half of 2027[8]

Forward-Looking Statements - The annual report includes forward-looking statements regarding future operations and financial performance, particularly related to seralutinib[15]. - The company does not plan to publicly update or revise forward-looking statements unless required by law[16]. - The report emphasizes the importance of not giving undue weight to estimates and projections due to inherent uncertainties[15]. - The report includes cautionary statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995[16]. Clinical Trials and Regulatory Filings - The company anticipates ongoing and planned preclinical studies and clinical trials for seralutinib, with regulatory filings and approvals expected in the near future[15]. Market Data and Estimates - Estimates and statistical data regarding market size and growth are included, but these involve assumptions and limitations[15]. - The report contains industry and market data derived from both internal estimates and independent research[18]. Risks and Uncertainties - The company acknowledges risks and uncertainties that may cause actual results to differ materially from projections[16]. Company Information - The company maintains a website for posting press releases and SEC filings, which are available free of charge[19]. - The company’s trademarks and tradenames are acknowledged, with a note on the convenience of their presentation in the report[17].

Company Overview - Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1] Product Development - The main drug in development is Seralutinib, which is an inhaled tyrosine kinase inhibitor targeting specific pathways related to PAH and PH-ILD [1]

Gossamer Bio (GOSS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

Core Viewpoint - Gossamer Bio (GOSS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance Indicators - Gossamer Bio is projected to earn -$0.28 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 76.3% [8]. - Over the past three months, the Zacks Consensus Estimate for Gossamer Bio has increased by 5.1%, indicating a positive outlook for the company [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Gossamer Bio's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10][11].

A downtrend has been apparent in Gossamer Bio (GOSS) lately with too much selling pressure. The stock has declined 20% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for ...

Core Viewpoint - Gossamer Bio (GOSS) has experienced a significant downtrend, with a 15.9% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Technical Indicators - GOSS shares have faced heavy selling pressure, indicated by an RSI reading of 19.78, suggesting that the stock may soon reverse its trend [5]. - The stock's RSI value indicates it is oversold, typically defined as an RSI reading below 30, which may present entry opportunities for investors [2][3]. - The consensus EPS estimate for GOSS has increased by 17% over the last 30 days, indicating a positive trend in earnings expectations that could lead to price appreciation [5]. Group 2: Analyst Ratings and Market Position - GOSS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [6].

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.23 per share when it actually produced earnings of $0.22, delivering a surprise of -4.35%.Over the last four quarters, the c ...